BCTXF Archives - BioTuesdays

Developments

BriaCell identifies new breast cancer responders based on cancer grade

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXD) identified a new group of patients with high levels of clinical benefit in response to its immunotherapy, and in combination with checkpoint inhibitors. After a reanalysis...

January 9, 2020

Developments

BriaCell announces clinical data at 2019 San Antonio Breast Cancer Symposium

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) presented results of clinical studies with its lead product candidate, Bria-IMT, in combination with immune checkpoint inhibitors in advanced breast cancer at 2019 San...

December 13, 2019

Developments

BriaCell to present clinical findings at San Antonio Breast Cancer Symposium

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) will highlight its lead product candidate, Bria-IMT, in two poster sessions during the 2019 San Antonio Breast Cancer Symposium. The Dec. 12 poster will summarize the data...

November 12, 2019

Developments

BriaCell doses first patient in advanced breast cancer combination study

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF)initiated dosing in a Phase 1/2a clinical study of its lead product candidate, Bria-IMT, in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced...

October 7, 2019

Developments

BriaCell presents remarkable responder data in combo study with KEYTRUDA

Dr. William Williams, president and CEO of BriaCell Therapeutics (TSX-V:BCT; OTCQB:BCTXF) presented clinical updates of its Phase 1/2a clinical trial of Bria-IMT, its lead drug candidate, in a combination study with...

September 19, 2019

Executive Moves

BriaCell Therapeutics names Richard Berman to board

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) appointed Richard Berman to its board of directors. Mr. Berman has more than 35 years of experience in venture capital; senior management; and mergers and acquisitions. He...

August 13, 2019

Feature

BriaCell advancing potential breakthrough immunotherapy for advanced breast cancer

By Len Zehr BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) has reported impressive early safety and efficacy data with its lead immunotherapies for the treatment of advanced breast cancer. “Right now, there is no...

May 21, 2019

Developments

BriaCell in publication at ASCO, presentation at breast cancer meeting

BriaCell Therapeutics’ (TSXV:BCT; OTCQB:BCTXF) clinical findings will be published in the 2019 American Society of Clinical Oncology (ASCO) annual meeting proceedings, a supplement to the Journal of Clinical Oncology...

April 23, 2019

Developments

BriaCell immunotherapy/KEYTRUDA combination increases anti-tumor activity in early trial

BriaCell Therapeutics (TSX-V:BCT) (OTCQB:BCTXF) announced that early Phase 1/2a data suggest its Bria-IMT immunotherapy, combined with the checkpoint inhibitor KEYTRUDA, demonstrated additive or synergistic anti-tumor...

April 3, 2019

Executive Moves

BriaCell Therapeutics names two biopharma experts to its board

BriaCell Therapeutics (TSV-V:BCT; OTCQB:BCTXF) appointed Dr. Rebecca Taub and Vaughn Embro-Pantalony as directors, and current board members Dr. Saeid Babaei, Rahoul Sharan, and Martin Schmieg have resigned, effective...

March 18, 2019

Tag - BCTXF

BriaCell identifies new breast cancer responders based on cancer grade

BriaCell announces clinical data at 2019 San Antonio Breast Cancer Symposium

BriaCell to present clinical findings at San Antonio Breast Cancer Symposium

BriaCell doses first patient in advanced breast cancer combination study

BriaCell presents remarkable responder data in combo study with KEYTRUDA

BriaCell Therapeutics names Richard Berman to board

BriaCell advancing potential breakthrough immunotherapy for advanced breast cancer

BriaCell in publication at ASCO, presentation at breast cancer meeting

BriaCell immunotherapy/KEYTRUDA combination increases anti-tumor activity in early trial

BriaCell Therapeutics names two biopharma experts to its board

General

More